

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		

### BIOCHEMISTRY

Test Name	Result	Unit	Biological Ref. Range	Sample: FI. Plasma
-----------	--------	------	-----------------------	--------------------

#### BLOOD GLUCOSE (FASTING)

BLOOD GLUCOSE (FASTING)	99.8	mg/dl	74 - 106
-------------------------	------	-------	----------

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

#### BLOOD GLUCOSE (PP )

BLOOD GLUCOSE (PP )	128.8	mg/dl	Non - Diabetic: - < 140 mg/dl Pre - Diabetic: - 140-199 mg/dl Diabetic: - >=200 mg/dl
---------------------	-------	-------	---

Sample: PLASMA

Method: Hexokinase assay.


Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

#### THYROID T3 T4 TSH

T3	1.600	ng/mL	0.970 - 1.690
T4	9.28	ug/dl	5.53 - 11.00
TSH	1.32	μIU/mL	0.40 - 4.05

Sample: Serum

RESULT ENTERED BY : NEETU SHARMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		

### BIOCHEMISTRY

**T3:-** Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in the diagnosis of T3-hyperthyroidism the detection of early stages of hyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

**T4:-** Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs a competitive test principle with an antibody specifically directed against T4.

**TSH - THYROID STIMULATING HORMONE :-** ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation:-The determination of TSH serves as the initial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

### LFT (LIVER FUNCTION TEST)

Sample: Serum

BILIRUBIN TOTAL	0.80	mg/dl	0.00 - 1.20
BILIRUBIN INDIRECT	0.62	mg/dl	0.20 - 1.00
BILIRUBIN DIRECT	0.18	mg/dl	0.00 - 0.40
SGOT	39.2	U/L	0.0 - 40.0
SGPT	<b>52.3 H</b>	U/L	0.0 - 40.0
TOTAL PROTEIN	7.4	g/dl	6.6 - 8.7
ALBUMIN	4.9	g/dl	3.5 - 5.2
GLOBULIN	2.5		1.8 - 3.6
ALKALINE PHOSPHATASE	106.6	U/L	53 - 128
A/G RATIO	2.0	Ratio	1.5 - 2.5
GGTP	40.6	U/L	10.0 - 55.0

RESULT ENTERED BY : NEETU SHARMA

*Abhinay Verma*

Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		

### BIOCHEMISTRY

**BILIRUBIN TOTAL** :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structure.

**BILIRUBIN DIRECT** :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

**SGOT - AST** :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT (AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

**SGPT - ALT** :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT (ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

**TOTAL PROTEINS** :- Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

**ALBUMIN** :- Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.


**ALKALINE PHOSPHATASE** :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. **GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE** :- Method:

Enzymatic colorimetric assay. Interpretation:- $\gamma$ -glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

### LIPID PROFILE

TOTAL CHOLESTEROL	222		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	24.7		High Risk :- <40 mg/dl (Male), <40 mg/dl (Female) Low Risk :- >=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	183.3		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	26.7	mg/dl	10 - 50
TRIGLYCERIDES	133.9		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	9.0	%	

RESULT ENTERED BY : NEETU SHARMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		

### BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders.

HDL CHOLESTEROL :- Method:-Homogenous enzymatic colorimetric method.

Interpretation:-HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived from VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.

CHOLESTEROL VLDL :- Method: VLDL Calculative

TRIGLYCERIDES :- Method: GPO-PAP enzymatic colorimetric assay.


Interpretation:-High triglyceride levels also occur in various diseases of liver, kidneys and pancreas. DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	18.6	mg/dl	16.60 - 48.50
BUN	8.7	mg/dl	6 - 20
CREATININE	0.82	mg/dl	0.60 - 1.10
SODIUM	138.0	mmol/L	136 - 145
POTASSIUM	4.20	mmol/L	3.50 - 5.50
CHLORIDE	104.7	mmol/L	98 - 107
URIC ACID	2.1 L	mg/dl	3.5 - 7.2
CALCIUM	9.49	mg/dl	8.60 - 10.30

RESULT ENTERED BY : NEETU SHARMA



Dr. ABHINAV VERMA

MBBS|MD|INCHARGE PATHOLOGY

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		

**CREATININE - SERUM** :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

**URIC ACID** :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation,drug abuse and increased alcohol consume.

**SODIUM**:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea,diminshed reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption.

**POTASSIUM** :- Method: ISE electrode. Intrapretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

**CHLORIDE - SERUM** :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake,prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

**UREA**:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

**CALCIUM TOTAL** :- Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usuallyassociated with hypercalcemia. Increased serum calcium levels may also beobserved in multiple myeloma and other neoplastic diseases. Hypocalcemia may beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

RESULT ENTERED BY : NEETU SHARMA

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		

### BLOOD BANK INVESTIGATION


Test Name	Result	Unit	Biological Ref. Range
-----------	--------	------	-----------------------

BLOOD GROUPING	"A" Rh Positive		
----------------	-----------------	--	--

Note :

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

RESULT ENTERED BY : NEETU SHARMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY


## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		

### CLINICAL PATHOLOGY

Test Name	Result	Unit	Biological Ref. Range	Sample: Urine
<b><u>URINE SUGAR (POST PRANDIAL)</u></b>				
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	Sample: Urine
<b><u>URINE SUGAR (RANDOM)</u></b>				
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	Sample: Urine
<b>PHYSICAL EXAMINATION</b>				
VOLUME	20	ml		Sample: Urine
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
<b>CHEMICAL EXAMINATION</b>				
PH	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
<b>MICROSCOPIC EXAMINATION</b>				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	0-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

RESULT ENTERED BY : NEETU SHARMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		


### CLINICAL PATHOLOGY

BACTERIA	NIL	NIL
OHTERS	NIL	NIL

Methodology:-

Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton release from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY : NEETU SHARMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY



## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		


### HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Range
<b><u>CBC (COMPLETE BLOOD COUNT)</u></b>			
Sample: WHOLE BLOOD EDTA			
HAEMOGLOBIN	14.9	g/dl	13.0 - 17.0
PACKED CELL VOLUME(PCV)	44.5	%	40.0 - 50.0
MCV	<b>92.7 H</b>	fl	82 - 92
MCH	31.0	pg	27 - 32
MCHC	33.5	g/dl	32 - 36
RBC COUNT	4.80	millions/cu.mm	4.50 - 5.50
TLC (TOTAL WBC COUNT)	7.71	10 <sup>3</sup> / uL	4 - 10
<b><u>DIFFERENTIAL LEUCOCYTE COUNT</u></b>			
NEUTROPHILS	49.5	%	40 - 80
LYMPHOCYTE	34.4	%	20 - 40
EOSINOPHILS	<b>10.4 H</b>	%	1 - 6
MONOCYTES	5.1	%	2 - 10
BASOPHIL	<b>0.6 L</b>	%	1 - 2
PLATELET COUNT	1.69	lakh/cumm	1.500 - 4.500

**HAEMOGLOBIN** :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.  
**MCV** :- Method:- Calculation bysystemex.  
**MCH** :- Method:- Calculation bysystemex.  
**MCHC** :- Method:- Calculation bysystemex.  
**RBC COUNT** :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia,High-Polycythemia.  
**TLC (TOTAL WBC COUNT)** :- Method:-Optical Detectorblock based on Flowcytometry.Interpretation:-High-Leucocytosis, Low-Leucopenia.  
**NEUTROPHILS** :- Method: Optical detectorblock based on Flowcytometry  
**LYMPHOCYTS** :- Method: Optical detectorblock based on Flowcytometry  
**EOSINOPHILS** :- Method: Optical detectorblock based on Flowcytometry  
**MONOCYTES** :- Method: Optical detectorblock based on Flowcytometry  
**BASOPHIL** :- Method: Optical detectorblock based on Flowcytometry  
**PLATELET COUNT** :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.  
**HCT**: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia.  
**NOTE**: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE)	15	mm/1st hr	0 - 15
--------------------------------------	----	-----------	--------

RESULT ENTERED BY : NEETU SHARMA



Dr. ABHINAY VERMA

MBBS|MD|INCHARGE PATHOLOGY

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	4014432
<b>UHID</b>	40007288	<b>Collection Date</b>	05/11/2023 9:16AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 9:41AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 1:13PM
<b>Referred By</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Report Status</b>	Final
<b>Mobile No.</b>	8094000135		

Method:-Modified Westergrens.

Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : NEETU SHARMA



## DEPARTMENT OF RADIO DIAGNOSIS

<b>UHID / IP NO</b>	40007288 (14002)	<b>RISNo./Status :</b>	4014432/
<b>Patient Name :</b>	Mr. JITENDRA SHARMA	<b>Age/Gender :</b>	42 Y/M
<b>Referred By :</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Ward/Bed No :</b>	OPD
<b>Bill Date/No :</b>	05/11/2023 9:01AM/ OPSCR23-24/7392	<b>Scan Date :</b>	
<b>Report Date :</b>	05/11/2023 10:14AM	<b>Company Name:</b>	Mediwheel - Arcofemi Health Care Ltd.

### ULTRASOUND STUDY OF WHOLE ABDOMEN

**Liver:** Normal in size & echotexture. **Simple cyst seen in right lobe, measuring approx. 16 x18 mm.** No obvious significant focal parenchymal mass lesion noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.

**Gall Bladder:** Lumen is clear. Wall thickness is normal. CBD is normal.

**Pancreas:** Normal in size & echotexture.

**Spleen:** Normal in size & echotexture. No focal lesion seen.

**Right Kidney:** Normal in shape, size & location. Echotexture is normal. Corticomedullary differentiation is maintained. No evidence of significant hydronephrosis or obstructive calculus noted.

**Left Kidney:** Normal in shape, size & location. Echotexture is normal. Corticomedullary differentiation is maintained. No evidence of significant hydronephrosis or obstructive calculus noted.

**Urinary Bladder:** Partially distended. No obvious calculus or mass lesion is seen.

**Prostate:** Is normal in size and echotexture.

**Others:** No significant free fluid is seen in pelvic peritoneal cavity.

**IMPRESSION: USG findings are suggestive of**

- **No obvious significant sonographic abnormality noted.**

**Correlate clinically & with other related investigations.**



**DR. APOORVA JETWANI**

**Incharge & Senior Consultant Radiology**

**MBBS, DMRD, DNB**

**Reg. No. 26466, 16307**

## DEPARTMENT OF CARDIOLOGY

<b>UHID / IP NO</b>	40007288 (14002)	<b>RISNo./Status :</b>	4014432/
<b>Patient Name :</b>	Mr. JITENDRA SHARMA	<b>Age/Gender :</b>	42 Y/M
<b>Referred By :</b>	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	<b>Ward/Bed No :</b>	OPD
<b>Bill Date/No :</b>	05/11/2023 9:01AM/ OPSCR23-24/7392	<b>Scan Date :</b>	
<b>Report Date :</b>	05/11/2023 12:16PM	<b>Company Name:</b>	Final

**REFERRAL REASON: - HEALTH CHECKUP**

### 2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

**M MODE DIMENSIONS: -**

		Normal		Normal
<b>IVSD</b>	9.9	6-12mm	<b>LVIDS</b>	26.7
<b>LVIDD</b>	40.3	32-57mm	<b>LVPWS</b>	17.2
<b>LVPWD</b>	11.3	6-12mm	<b>AO</b>	31.7
<b>IVSS</b>	17.7	mm	<b>LA</b>	29.0
<b>LVEF</b>	62-64	>55%	<b>RA</b>	-

### DOPPLER MEASUREMENTS & CALCULATIONS:

STRUCTURE	MORPHOLOGY	VELOCITY (m/s)				GRADIENT (mmHg)	REGURGITATION
		E	A	e'	E/e'		
MITRAL VALVE	NORMAL	0.93		e'		-	NIL
		0.65		E/e'			
TRICUSPID VALVE	NORMAL	E		0.64		-	NIL
		A		0.59			
AORTIC VALVE	NORMAL	1.04				-	NIL
PULMONARY VALVE	NORMAL	0.77				-	NIL

**COMMENTS & CONCLUSION: -**

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

**IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS**

**DR SUPRIY JAIN**  
**MBBS, M.D., D.M. (CARDIOLOGY)**  
**INCHARGE & SR. CONSULTANT**  
**INTERVENTIONAL CARDIOLOGY**

**DR ROOPAM SHARMA**  
**MBBS, PGDCC, FIAE**  
**CONSULTANT & INCHARGE**  
**EMERGENCY, PREVENTIVE CARDIOLOGY**  
**AND WELLNESS CENTRE**

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	563298
<b>UHID</b>	326724	<b>Collection Date</b>	05/11/2023 10:44AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 10:45AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 11:20AM
<b>Referred By</b>	Dr. EHCC Consultant	<b>Report Status</b>	Final
<b>Mobile No.</b>	9773349797		



MC-2561

### BIOCHEMISTRY

Test Name	Result	Unit	Biological Ref. Range
HBA1C	5.3	%	< 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes
			Known Diabetic Patients < 7 % Excellent Control 7 - 8 % Good Control > 8 % Poor Control

Sample: WHOLE BLOOD EDTA

Method : - High - performance liquid chromatography HPLC

Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient.  
The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

**\*\*End Of Report\*\***

RESULT ENTERED BY : Mr. PANKAJ SHUKLA

Dr. SURENDRA SINGH  
CONSULTANT & HOD  
MBBS|MD| PATHOLOGY

Dr. ASHISH SHARMA  
CONSULTANT & INCHARGE PATHOLOGY  
MBBS|MD| PATHOLOGY

## ETERNAL HOSPITAL MEDICAL TESTING LABORATORY

<b>Patient Name</b>	Mr. JITENDRA SHARMA	<b>Lab No</b>	563298
<b>UHID</b>	326724	<b>Collection Date</b>	05/11/2023 10:44AM
<b>Age/Gender</b>	42 Yrs/Male	<b>Receiving Date</b>	05/11/2023 10:45AM
<b>IP/OP Location</b>	O-OPD	<b>Report Date</b>	05/11/2023 12:52PM
<b>Referred By</b>	Dr. EHCC Consultant	<b>Report Status</b>	Final
<b>Mobile No.</b>	9773349797		



### BIOCHEMISTRY

Test Name	Result	Unit	Biological Ref. Range	Sample: Serum
PSA (TOTAL)	1.07	ng/mL	0.00 - 4.00	

Total (Free + complexed) PSA - Prostate specific antigen (tPSA)

Method : ElectroChemiluminescence ImmunoAssay - ECLIA

Interpretation:-PSA determinations are employed are the monitoring of progress and efficiency of therapy in patients with prostate carcinoma or receiving hormonal therapy.

**\*\*End Of Report\*\***

RESULT ENTERED BY : Mr. PANKAJ SHUKLA

Dr. SURENDRA SINGH  
CONSULTANT & HOD  
MBBS|MD| PATHOLOGY

Dr. ASHISH SHARMA  
CONSULTANT & INCHARGE PATHOLOGY  
MBBS|MD| PATHOLOGY